Overcoming Ligand Discovery Challenges: Developing Peptide-Based Tracers for SPSB2

Developing new E3 ligase ligands for the design of heterobivalent molecules, such as PROteolysis TArgeting Chimeras (PROTACs), requires careful evaluation of target engagement (TE). Characterizing protein-protein interactions (PPIs) is therefore essential in drug discovery, as it enables the assessment of ligand binding to sites that are often difficult to target. Degrons, peptide motifs recognized by E3 ligases, may serve as valuable starting points for designing E3 ligands. However, many degrons are highly polar and lack intrinsic membrane permeability, requiring alternative strategies for efficient cellular delivery. In this study, we used the SPRY domain-containing SOCS box protein 2 (SPSB2) E3 ligase as a model system to develop TE strategies <i>in vitro</i> and <i>in cellulo</i> using polar degron-based peptides. By conjugating various polycationic cell-penetrating peptides (CPPs) to the degron sequence, we present a study demonstrating cellular delivery. We obtained a high-resolution crystal structure and used various biophysical techniques to assess the influence of each modification, while confocal microscopy and BRET-based assays confirmed successful cellular delivery as well as potent TE.

Authors

Institutions

Publication Details

Journal
ACS Chemical Biology
Published
2025-12-08
DOI
https://doi.org/10.1021/acschembio.5c00702
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Overcoming Ligand Discovery Challenges: Developing Peptide-Based Tracers for SPSB2

Frank Löhr, Stefan Knapp, Krishna Saxena, Volker Dötsch et al.
ACS Chemical Biology
Protein Degradation and Inhibitors
article

Overcoming Ligand Discovery Challenges: Developing Peptide-Based Tracers for SPSB2

Frank Löhr, Stefan Knapp, Krishna Saxena, Volker Dötsch, Christopher Lenz, Herbert Waldmann, Stéphanie M. Guéret, Susanne Müller, Lewis Elson, Frederic Farges, Andreas Krämer, Johannes Dopfer
article en

Abstract

Developing new E3 ligase ligands for the design of heterobivalent molecules, such as PROteolysis TArgeting Chimeras (PROTACs), requires careful evaluation of target engagement (TE). Characterizing protein-protein interactions (PPIs) is therefore essential in drug discovery, as it enables the assessment of ligand binding to sites that are often difficult to target. Degrons, peptide motifs recognized by E3 ligases, may serve as valuable starting points for designing E3 ligands. However, many degrons are highly polar and lack intrinsic membrane permeability, requiring alternative strategies for efficient cellular delivery. In this study, we used the SPRY domain-containing SOCS box protein 2 (SPSB2) E3 ligase as a model system to develop TE strategies <i>in vitro</i> and <i>in cellulo</i> using polar degron-based peptides. By conjugating various polycationic cell-penetrating peptides (CPPs) to the degron sequence, we present a study demonstrating cellular delivery. We obtained a high-resolution crystal structure and used various biophysical techniques to assess the influence of each modification, while confocal microscopy and BRET-based assays confirmed successful cellular delivery as well as potent TE.

ACS Chemical BiologyVol. 21(2)
Goethe University Frankfurt (DE), TU Dortmund University (DE), AstraZeneca (Brazil) (BR), Max Planck Institute of Molecular Physiology (DE), AstraZeneca (Finland) (FI)
Openalex Percentile: Top 65%
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.